NICE approves bendamustine for chronic lymphocytic leukaemia
Bendamustine is now recommended for the first-line treatment of some chronic cancer patients, according to guidance from the National Institute for Health and Clinical Excellence.
The drug, launched last August under the brand name Levact (Napp Pharmaceuticals), can be used in the NHS in England and Wales to treat patients with previously untreated chronic lymphocytic leukaemia (Binet stage B or C) who cannot receive fludarabine combination chemotherapy.
NICE rejected bendamustine in October 2010 for the treatment of non-Hodgkin’s lymphoma that is refractory to rituximab or a rituximab-containing regimen.
Citation: The Pharmaceutical Journal URI: 11069672